Navigation Links
Asymmetrex Publishes Chapter Explaining the Critical Need for Stem Cell Dosing for Success in Stem Cell Medicine
Date:1/10/2019

When Dr. James L. Sherley, M.D., Ph.D., founder and director of Massachusetts stem cell biotechnology company Asymmetrex, was invited to contribute a chapter to the new book Perinatal Stem Cells: Research and Therapy, he knew immediately what his topic would be. “I wanted to continue Asymmetrex’s effort to address a debilitating secret of stem cell medicine. For more than a half-century, stem cell medicine has tried to advance without knowing the dose of stem cells in stem cell treatments.”

Although it is inconceivable that patients in any other medical setting would be administered drugs or medicines without knowing their dose – number of drug molecules, weight of medicines – this otherwise unacceptable practice is usual for stem cell treatments. Whether they are approved treatments like bone marrow and cord blood transplants, or new treatments evaluated in clinical trials, or controversial treatments offered in private stem cell clinics, in all cases, the dose of stem cells administered to patients is unknown.

The tissue stem cell dose problem is not limited to clinical applications either. Upstream of medical and clinical uses, stem cell preparations are also supplied without knowing the number of stem cells contained in them.

In the recently published book chapter, “Dose Determination for Stem Cell Medicine: A Need Whose Time Has Come,” Sherley discusses why this situation exists and persists. He describes “pseudo-dosing” as the practical response by the field of stem cell medicine and the stem cell supply industry to the previously unsolvable problem of counting therapeutic tissue stem cells specifically and accurately.

Pseudo-dosing comes in many forms, but the most common is due to tests that do not count tissue stem cells specifically. Existing widely-used, but misnamed, “stem cell biomarkers,” “stem cell assays”, and even “stem cell counts” have contributed to the surprisingly commonly-held misconception that therapeutic stem cell counting and dose determination occurs routinely as for other medical treatments. Sherley’s chapter emphasizes that nothing could be farther from the truth; and goes on to outline the tremendous losses in treatment quality and stem cell medical progress caused by this remarkable misunderstanding.

Education to correct the misconception that stem cell counting and stem cell dosing have been in place all along can improve progress in stem cell medicine. However, Sherley points out that education about emerging new technologies for specific counting of tissue stem cells would have an even greater impact. The chapter also describes novel strategies for discovery of specific stem cell biomarkers and Asymmetrex’s recent development of a computational method for counting adult tissue stem cells for the first time. Director Sherley and his AlphaSTEM Test™ team anticipate that instilling a better understanding of the long-standing stem cell counting and dosing problem will motivate more rapid evaluation and adoption of the long-needed, if not necessarily long-awaited, solution.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Read the full story at https://www.prweb.com/releases/asymmetrex_publishes_chapter_explaining_the_critical_need_for_stem_cell_dosing_for_success_in_stem_cell_medicine/prweb16025065.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About CRISPR-Cas9 Gene-Editing Therapies
2. Asymmetrex Proposes “Stemgene Therapy” to Emphasize the Importance of Tissue Stem Cells for Successful Gene Therapy
3. As Part of the Evolving CiPA Paradigm, the FDA Publishes Results Validating the Utility of hiPSC-cardiomyocytes to Detect Drug-induced Proarrhythmia
4. BellBrook Labs Publishes “A Guide to Measuring Drug-Target Residence Times with Biochemical Assays”
5. Connected Health Pioneer, Dr. Joe Kvedar, Publishes First Book, The Internet Of Healthy Things, Focusing On Technology-Enabled Health And Wellness, Trends And Business Opportunities
6. Taxonomy -- the Leopoldina publishes recommendations on researching biodiversity
7. University of Houston researcher publishes textbook on tissue engineering
8. Endocrine Press publishes guide to treating metabolic emergencies
9. Chapman University affiliated physicist publishes on the Aharonov-Bohm effect in Nature
10. Open science journal publishes attempt to reproduce high-profile stem cell acid bath study
11. EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2019)... ... March 08, 2019 , ... On International Women’s Day, ... initiative focused on women in the field. The Women in Cancer Immunotherapy ... celebrate and empower emerging female leaders in the cancer immunotherapy field. , Scheduled ...
(Date:3/1/2019)... ... 28, 2019 , ... Teresa Krabbe, Ph.D., a student in the working group ... has been awarded an xCELLigence Research Grant for her proposal to develop adoptive T ... , Oncolytic viruses represent an exciting new aspect in the evolving field of cancer ...
(Date:2/22/2019)... ... February 20, 2019 , ... ... and precision medicine, the traditional line between engineering and medical science grows ever ... and smarter, the medical device industry is making medical practice easier for doctors, ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... Calif. (PRWEB) , ... March 19, 2019 , ... ... Konica Minolta, Inc. (Konica Minolta) today announced the formation of their inaugural Scientific ... the advancement of precision medicine that takes into account individual variability in genes, ...
(Date:3/18/2019)... Calif. (PRWEB) , ... March 18, 2019 , ... For ... partnered together to develop solutions that allow life science companies to easily comply with ... USDM’s Cloud Assurance ™ is a managed service delivering end-to-end GxP compliance from ...
(Date:3/14/2019)... ... March 14, 2019 , ... Open registration for the Case ... Spectrum of Case Management,” continues as CMSA makes plans to host the annual ... case management industry conference serving the educational and networking needs of case and ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... solution for preclinical research organizations. It is a low code, GDPR/21 CFR ... and facilities, innovative technology-driven automated data capture and seamless data and information ...
Breaking Biology Technology: